This study presented the treatment results of 91 patients with craniopharyngioma received proton therapy after tumor resection (88 patients, 97%), as an adjuvant strategy (64 patients, 70.3%) and for recurrent disease (27 patients, 29.7%). With a median follow-up of 39 months, the 5-year LRFS was 92.0%. Endocrinopathy was the most frequent grade ≥ 2 late toxicity. Four (9.8%) developed visual disorders and 10 (11.3%) symptomatic memory impairment.